Estimating the maximal solubility advantage of drug salts

被引:7
|
作者
Skrdla, Peter J. [1 ]
机构
[1] GlaxoSmithKline, 1250 S Collegeville Rd, Collegeville, PA 19426 USA
关键词
Salt; API; Counterion; Solubility; Enhancement; Simulation;
D O I
10.1016/j.ijpharm.2021.120228
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Salt formation can enable the development of poorly water-soluble drugs containing at least one ionizable moiety. Not only can salts offer a solubility enhancement that can sometimes far exceed that of other commonly used solubilization strategies applied across the pharmaceutical industry, they can simultaneously bestow additional benefits such as providing low-cost formulation options. The goal of this work is to put forth a simple methodology to enable one to accurately predict the maximal solubility advantage of acidic and basic drugs whose unionized conjugate (neutral parent molecule) is poorly soluble. While published equations leveraging the Henderson-Hasselbalch/H-H relationship reasonably estimate the thermodynamic solubility limit (in systems where there is no supersaturation), under physiologically relevant conditions the maximal/kinetic solubility can play an important role in determining oral bioavailability, as in the case of amorphous drugs. Under these circumstances, a higher solubility can be maintained for short durations through drug supersaturation provided that the precipitation is slow, thereby causing deviations from H-H predictions. It is possible also that, in some instances, supersaturation could coincide with behavior previously attributed to drug aggregation in solution. The proposed methodology utilizes speciation across the pH range to allow one to determine the maximal amount of ionized and unionized drug in solution at each pH. The calculation is easily extended to cases where the counterion serves as a competing weak acid, weak base, or as a common ion. Additionally, a more thorough assessment of the Gibbs free energy change associated with the solubilization of salts is also presented, as this energy describes the key driving force for the recrystallization of the neutral parent by triggering its nucleation. Lastly, to demonstrate applicability to real-world compounds containing multiple ionizable moieties, the complex pH-solubility profile of a drug maleate salt taken from the literature is simulated.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Solubility and Stability Advantage of Aceclofenac Salts
    Goud, N. Rajesh
    Suresh, Kuthuru
    Nangia, Ashwini
    CRYSTAL GROWTH & DESIGN, 2013, 13 (04) : 1590 - 1601
  • [2] Salts and Cocrystal of Etodolac: Advantage of Solubility, Dissolution, and Permeability
    Rai, Sunil K.
    Allu, Suryanarayana
    Nangia, Ashwini K.
    CRYSTAL GROWTH & DESIGN, 2020, 20 (07) : 4512 - 4522
  • [3] Solubility Advantage of Tenoxicam Phenolic Cocrystals Compared to Salts
    Bolla, Geetha
    Sanphui, Palash
    Nangia, Ashwini
    CRYSTAL GROWTH & DESIGN, 2013, 13 (05) : 1988 - 2003
  • [4] Estimating drug solubility in the gastrointestinal tract
    Dressman, J. B.
    Vertzoni, M.
    Goumas, K.
    Reppas, C.
    ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (07) : 591 - 602
  • [5] ENHANCEMENT OF SOLUBILITY OF DRUG SALTS BY HYDROPHILIC COUNTERIONS - PROPERTIES OF ORGANIC SALTS OF AN ANTIMALARIAL DRUG
    AGHARKAR, S
    LINDENBAUM, S
    HIGUCHI, T
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1976, 65 (05) : 747 - 749
  • [6] THE EFFECT OF SALTS ON THE DISTRIBUTION AND SOLUBILITY OF AN ACIDIC DRUG
    PANDIT, NK
    STRYKOWSKI, JM
    SHTOHRYN, L
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1989, 50 (01) : 7 - 13
  • [7] High-Solubility Salts of the Multiple Sclerosis Drug Teriflunomide
    Gunnam, Anilkumar
    Nangia, Ashwini K.
    CRYSTAL GROWTH & DESIGN, 2019, 19 (09) : 5407 - 5417
  • [8] Taking advantage of solvate formation to modulate drug-drug ratio in clofaziminium diclofenac salts
    Bodart, Laurie
    Prinzo, Maria
    Derlet, Amelie
    Tumanov, Nikolay
    Wouters, Johan
    CRYSTENGCOMM, 2021, 23 (01) : 185 - 201
  • [9] Molecular Dynamics, Physical Stability and Solubility Advantage from Amorphous Indapamide Drug
    Wojnarowska, Z.
    Grzybowska, K.
    Hawelek, L.
    Dulski, M.
    Wrzalik, R.
    Gruszka, I.
    Paluch, M.
    Pienkowska, K.
    Sawicki, W.
    Bujak, P.
    Paluch, K. J.
    Tajber, L.
    Markowski, J.
    MOLECULAR PHARMACEUTICS, 2013, 10 (10) : 3612 - 3627
  • [10] Novel Salts of the Atypical Antipsychotic Drug Lurasidone with Improved Solubility and Bioavailability
    Guo, Chunyang
    Wang, Yuan
    Xie, Junyi
    Zhu, Bin
    Qi, Ming-Hui
    Hong, Minghuang
    Ren, Guo-Bin
    CRYSTAL GROWTH & DESIGN, 2023, 23 (01) : 326 - 332